HDAC-IN-4 is a selective HDAC6 and HDAC10 inhibitor with pIC50s of 7.2 and 6.8 in BRET assay, respectively. Antitumoral activity.

Product information

CAS Number: 1252003-13-6

Molecular Weight: 335.40

Formula: C20H21N3O2

Chemical Name: N-hydroxy-4-({2-methyl-1H, 2H, 3H, 4H, 9H-pyrido[3, 4-b]indol-9-yl}methyl)benzamide

Smiles: CN1CC2=C(CC1)C1=CC=CC=C1N2CC1=CC=C(C=C1)C(=O)NO

InChiKey: JVELXRPQMVXDDP-UHFFFAOYSA-N

InChi: InChI=1S/C20H21N3O2/c1-22-11-10-17-16-4-2-3-5-18(16)23(19(17)13-22)12-14-6-8-15(9-7-14)20(24)21-25/h2-9,25H,10-13H2,1H3,(H,21,24)

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

HDAC-IN-4 inhibits HDAC1, HDAC2, HDAC3, HDAC8 and HDAC10 with pIC50s of 5.5, 4.6, 5.4, 5.4, 6.7 in FRET assay, respectively. HDAC-IN-4 is more potent against HDAC6 than Tubastatin A, suggests that HDAC-IN-4 may be a better HDAC6 probe than Tubastatin A.

Products are for research use only. Not for human use.